

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/078357 A1

(51) International Patent Classification:
C07K 16/46 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/CN2021/123438

(22) International Filing Date:
13 October 2021 (13.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2020/120918
14 October 2020 (14.10.2020) CN
PCT/CN2021/085335
02 April 2021 (02.04.2021) CN

(71) Applicant: **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD** [CN/CN]; No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(72) Inventors: **LIU, Baihong**; No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **YANG, Yi**; No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **SHEN, Yuele**; No.12 Baoshen South

Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(74) Agent: **BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP)**; 12B17 12th Floor, Building 1, Courtyard 13, Dazhongsi, Haidian District, Beijing 100098 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-PD-1/CD40 BISPECIFIC ANTIBODIES AND USES THEREOF




FIG. 1B

(57) Abstract: This disclosure relates to antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof), wherein the antigen-binding protein constructs specifically bind to two different antigens (e.g., PD-1 and CD40).



WO 2022/078357 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*